These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37240048)

  • 1. Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.
    Membrive-Jiménez C; Pérez-Ramírez C; Arias-Santiago S; Richetta AG; Ottini L; Pineda-Lancheros LE; Ramírez-Tortosa MDC; Jiménez-Morales A
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
    van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
    Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
    Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
    J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
    Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics; 2015; 16(15):1723-31. PubMed ID: 26415694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
    J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
    Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
    Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept.
    Guarene M; Pasi A; Bolcato V; Cananzi R; Piccolo A; Sbarsi I; Klersy C; Cacciatore R; Brazzelli V
    Mol Diagn Ther; 2018 Aug; 22(4):471-474. PubMed ID: 29943154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.
    Membrive Jiménez C; Pérez Ramírez C; Sánchez Martín A; Vieira Maroun S; Arias Santiago SA; Ramírez Tortosa MDC; Jiménez Morales A
    J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33921427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis.
    Julià A; Ferrándiz C; Dauden E; Fonseca E; Fernández-López E; Sanchez-Carazo JL; Vanaclocha F; Puig L; Moreno-Ramírez D; Lopez-Estebaranz JL; Herrera E; de la Cueva P; Ávila G; Alonso A; Tortosa R; López-Lasanta M; Marsal S
    Pharmacogenomics J; 2015 Aug; 15(4):322-5. PubMed ID: 25403996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study.
    Cozzani E; Wei Y; Burlando M; Signori A; Parodi A
    J Am Acad Dermatol; 2020 Jan; 82(1):37-44. PubMed ID: 31150706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
    Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
    J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.